Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer

BACKGROUND: We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). METHODS: TTP RNA expression was measured in an RP cohort of patients treated at Moffitt Cance...

詳細記述

保存先:
書誌詳細
出版年:Cancer Epidemiol Biomarkers Prev
主要な著者: Rounbehler, Robert J., Berglund, Anders E., Gerke, Travis, Takhar, Mandeep M., Awasthi, Shivanshu, Li, Weimin, Davicioni, Elai, Erho, Nicholas G., Ross, Ashley E., Schaeffer, Edward M., Klein, Eric A., Karnes, R. Jeffrey, Jenkins, Robert B., Cleveland, John L., Park, Jong Y., Yamoah, Kosj
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214732/
https://ncbi.nlm.nih.gov/pubmed/30108099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-18-0369
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料